Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction (Centre Daily Times)
Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced the final two-year results for the Company’s trial evaluating Prochymal ® for the treatment of acute myocardial infarction. Prochymal is a proprietary formulation of adult stem cells designed to provide therapeutic benefit by controlling inflammation, promoting tissue regeneration, and preventing scar formation. This double-blind, …
[Read the full article here]Related News:
First Patient Treated In Osiris Phase II Stem Cell Trial For Heart Attacks
Advances in combination adult stem cell treatment for acute myocardial infarction presented at SCAI
Osiris Therapeutics Completes Enrollment Of Stem Cell Trial For The Treatment Of Heart Attacks